- published: 23 Mar 2015
- views: 3164
Create your page here
-
remove the playlistBiogen Idec
- remove the playlistBiogen Idec
back to playlist
One of the original biotech companies, Biogen has been anchored in Cambridge, MA for nearly four decades. Today, we remain committed to our roots in science and innovation – and to bringing forward new medicines that will have a real impact on patients, caregivers and society. To us, that is science that truly matters. http://www.biogen.com
Dr. Barry Hendin, Chief of Neurology Service, Banner Good Samaritan Hospital and Clinical Professor of Neurology, University of Arizona comments on the U.S. FDA approval of Biogen Idec's TECFIDERA(TM) (dimethyl fumarate) for relapsing multiple sclerosis
http://www.businesswire.com/news/home/20130327006385/en/Biogen-Idec%E2%80%99s-TECFIDERA%E2%84%A2-Dimethyl-Fumarate-Approved-First-Line
- published: 28 Mar 2013
- views: 1814
Breaking Wave is an anamorphic kinetic sculpture created for our new headquarters in Cambridge, MA by Plebian Design and Hypersonic. If you’d like to visit in person, Breaking Wave runs Monday through Friday, 8am to 8pm at 255 Binney St. in Cambridge, MA. The sculpture is viewable from the street, or from inside the lobby. Feel free to ask the guards where the hidden images are, if you don’t find them.
Breaking Wave tells the story of the search for patterns, and the surprising results that come by changing our point of view. 804 suspended spheres move in a wave-like formation. When the wave crests and breaks, the balls hover momentarily in a cloud. From almost anywhere in the room, this cloud is purely chaotic, but step into one of two hidden spots, and this apparent chaos shows a hidden pattern. From the first, a labyrinth hints at the search for knowledge, and from the second, a Fibonacci spiral inspired flower reminds us of the natural order and patterns found in nature.
Scientists search through billions of experimental data points in order to find patterns to develop new drugs, to treat diseases. Without a particular framework or perspective, these are just 0’s and 1’s, with no form or information. But with the perspective of an understanding of molecular dynamics, these data points create a clear picture about the hidden dynamics within the body, and allow scientists to craft drugs to successfully treat these diseases.
This concept was designed with pencil, paper, and processing. The structure was designed in Solidworks. The piece was built with many hands, and several miles of wire rope.
Please check out "Order from Chaos" vimeo.com/102339558 for a making-of video by Alberta Chu's ASKlabs.
To learn more about the project a link to the project visit:
http://www.hypersonic.cc/projects/breakingwave
Credits:
Breaking Wave by Plebian Design and Hypersonic
Project Management Small Design Firm
Lighting Design David Weiner Design
Material Development Lightfast D B
Concept Rendering Carl Albrecht
The creators of the video send a special thanks to:
Ed Dondero, Melissa Kendis, and Dan McIntyre at Biogen-Idec, Jenna Fizel, Nathan Lachenmyer, David Small, Heather Blind, Alberta Chu, Kasumi Hinouchi, Neal Mayer, Lauren McCarthy, Kyle McDonald, JB Michel, Dan Paluska, Chris Parlato, Plus Fabrication, Scott Taylor, Sosolimited, Chris Danemayer.
Music by knolls
- published: 04 Sep 2014
- views: 53801
Discover how Biogen Idec's industry-recognized expertise in manufacturing biologic therapies blends a combination of innovation and collaboration to ensure quality and reliable drugs.
- published: 02 Feb 2012
- views: 17187
June 21 (Bloomberg) -- Phillip Sharp, co-founder of Biogen Idec Inc. and Alnylam Pharmaceuticals Inc., talks with Bloomberg's Mark Crumpton about the possibility that Biogen could be acquired and the outlook for the biotechnology industry and Alnylam.
Sharp retired from the board of Biogen last year and remains a board member at Alnylam. He won the Nobel Prize in Medicine in 1993 and is a biology professor at Massachusetts Institute of Technology. (Source: Bloomberg)
- published: 23 Mar 2012
- views: 429
Hear Ester Algeria from Biogen Idec explain why the pharmaceutical company has chosen to place a large production site in Denmark to benefit from the strong Danish biotech cluster and not least the large talent pool.
Biogen Idec is a leading global biotechnological company with around 400 employees in Denmark working within fields like the production of pharmaceuticals for the treatment of multiple scleroses and biosimilars.
Read more at www.investindk.com
- published: 25 Apr 2013
- views: 688
This September Biogen Idec held it's 4th Annual Care Deeply Day, where employees volunteer across the globe in their local communities.
The Biogen Idec Care Deeply Volunteer Day is part of the company’s philanthropic focus on patients, science education and supporting local community needs.
This was our largest Care Deeply Day ever with over 2900 employees participating in over 140 Projects, volunteering over 14,500 hours in 27 countries. #CareDeeplyDay
- published: 03 Oct 2014
- views: 1665
Biogen Idec, Inc. (NASDAQ: BIIB) is an American biotechnology company specializing in drugs for neurological disorders, autoimmune disorders and cancer. The company was formed in 2003 by the merger of Cambridge, Massachusetts-based Biogen Inc. and San Diego, California-based IDEC Pharmaceuticals (formed in 1986 by biotech pioneers Ivor Royston and Howard Birndorf). Biogen, one of the oldest biotechnology companies, was founded in 1978 in Geneva by several biologists, including Phillip Sharp of the Massachusetts Institute of Technology, Walter Gilbert of Harvard (who served as CEO during the start-up phase) and Charles Weissmann of Zurich University (who contributed the first product interferon-alpha).
Biogen Idec stock is a component of several stock indices such as the S&P 500, S&P 1500, and NASDAQ-100.
Biogen Idec's products include multiple sclerosis (MS) treatments Avonex (interferon beta-1a) and Tysabri (natalizumab); the latter is also approved for treatment of Crohn's disease, and is co-marketed with Élan. Biogen Idec also makes Rituxan (rituximab), a treatment for non-Hodgkin's lymphoma which is also approved for rheumatoid arthritis; Rituxan is co-marketed with Genentech. The company acquired Fumaderm (fumaric acid esters), a psoriasis treatment (licensed in Germany) when it acquired Fumapharm AG in 2006. In December, 2007, Biogen Idec sold the U.S. rights for Zevalin (ibritumomab tiuxetan), another treatment for non-Hodgkin's lymphoma, to Cell Therapeutics, but continues to produce it for European marketing partner Bayer Schering Pharma. In 2006, the company sold rights for Amevive (alefacept), another psoriasis treatment, to Astellas Pharma, continuing to manufacture the drug under contract.
This page contains text from Wikipedia, the Free Encyclopedia -
http://en.wikipedia.org/wiki/Biogen_Idec
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
This article is licensed under the Creative Commons Attribution-ShareAlike 3.0 Unported License, which means that you can copy and modify it as long as the entire work (including additions) remains under this license.
- Loading...
-
1:31Biogen Idec is Biogen, Once Again
Biogen Idec is Biogen, Once AgainBiogen Idec is Biogen, Once Again
One of the original biotech companies, Biogen has been anchored in Cambridge, MA for nearly four decades. Today, we remain committed to our roots in science and innovation – and to bringing forward new medicines that will have a real impact on patients, caregivers and society. To us, that is science that truly matters. http://www.biogen.com -
3:21Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US for Multiple Sclerosis
Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US for Multiple SclerosisBiogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US for Multiple Sclerosis
Dr. Barry Hendin, Chief of Neurology Service, Banner Good Samaritan Hospital and Clinical Professor of Neurology, University of Arizona comments on the U.S. FDA approval of Biogen Idec's TECFIDERA(TM) (dimethyl fumarate) for relapsing multiple sclerosis http://www.businesswire.com/news/home/20130327006385/en/Biogen-Idec%E2%80%99s-TECFIDERA%E2%84%A2-Dimethyl-Fumarate-Approved-First-Line -
3:29Breaking Wave, kinetic sculpture located in the Biogen Idec lobby
Breaking Wave, kinetic sculpture located in the Biogen Idec lobbyBreaking Wave, kinetic sculpture located in the Biogen Idec lobby
Breaking Wave is an anamorphic kinetic sculpture created for our new headquarters in Cambridge, MA by Plebian Design and Hypersonic. If you’d like to visit in person, Breaking Wave runs Monday through Friday, 8am to 8pm at 255 Binney St. in Cambridge, MA. The sculpture is viewable from the street, or from inside the lobby. Feel free to ask the guards where the hidden images are, if you don’t find them. Breaking Wave tells the story of the search for patterns, and the surprising results that come by changing our point of view. 804 suspended spheres move in a wave-like formation. When the wave crests and breaks, the balls hover momentarily in a cloud. From almost anywhere in the room, this cloud is purely chaotic, but step into one of two hidden spots, and this apparent chaos shows a hidden pattern. From the first, a labyrinth hints at the search for knowledge, and from the second, a Fibonacci spiral inspired flower reminds us of the natural order and patterns found in nature. Scientists search through billions of experimental data points in order to find patterns to develop new drugs, to treat diseases. Without a particular framework or perspective, these are just 0’s and 1’s, with no form or information. But with the perspective of an understanding of molecular dynamics, these data points create a clear picture about the hidden dynamics within the body, and allow scientists to craft drugs to successfully treat these diseases. This concept was designed with pencil, paper, and processing. The structure was designed in Solidworks. The piece was built with many hands, and several miles of wire rope. Please check out "Order from Chaos" vimeo.com/102339558 for a making-of video by Alberta Chu's ASKlabs. To learn more about the project a link to the project visit: http://www.hypersonic.cc/projects/breakingwave Credits: Breaking Wave by Plebian Design and Hypersonic Project Management Small Design Firm Lighting Design David Weiner Design Material Development Lightfast D B Concept Rendering Carl Albrecht The creators of the video send a special thanks to: Ed Dondero, Melissa Kendis, and Dan McIntyre at Biogen-Idec, Jenna Fizel, Nathan Lachenmyer, David Small, Heather Blind, Alberta Chu, Kasumi Hinouchi, Neal Mayer, Lauren McCarthy, Kyle McDonald, JB Michel, Dan Paluska, Chris Parlato, Plus Fabrication, Scott Taylor, Sosolimited, Chris Danemayer. Music by knolls -
3:15Manufacturing Drugs at Large Scale
Manufacturing Drugs at Large ScaleManufacturing Drugs at Large Scale
Discover how Biogen Idec's industry-recognized expertise in manufacturing biologic therapies blends a combination of innovation and collaboration to ensure quality and reliable drugs. -
2:28The Next Big Thing In Biotech: Biogen Idec
The Next Big Thing In Biotech: Biogen Idec -
5:05Sharp Says Biogen Idec Can Grow Alone or Be Acquired: Video
Sharp Says Biogen Idec Can Grow Alone or Be Acquired: VideoSharp Says Biogen Idec Can Grow Alone or Be Acquired: Video
June 21 (Bloomberg) -- Phillip Sharp, co-founder of Biogen Idec Inc. and Alnylam Pharmaceuticals Inc., talks with Bloomberg's Mark Crumpton about the possibility that Biogen could be acquired and the outlook for the biotechnology industry and Alnylam. Sharp retired from the board of Biogen last year and remains a board member at Alnylam. He won the Nobel Prize in Medicine in 1993 and is a biology professor at Massachusetts Institute of Technology. (Source: Bloomberg) -
4:37(BIIB) Biogen Idec, Inc.
(BIIB) Biogen Idec, Inc. -
6:27(BIIB) Biogen Idec, Inc.
(BIIB) Biogen Idec, Inc. -
2:26Biogen Idec Tapping into Denmark's Strong Biotech Cluster
Biogen Idec Tapping into Denmark's Strong Biotech ClusterBiogen Idec Tapping into Denmark's Strong Biotech Cluster
Hear Ester Algeria from Biogen Idec explain why the pharmaceutical company has chosen to place a large production site in Denmark to benefit from the strong Danish biotech cluster and not least the large talent pool. Biogen Idec is a leading global biotechnological company with around 400 employees in Denmark working within fields like the production of pharmaceuticals for the treatment of multiple scleroses and biosimilars. Read more at www.investindk.com -
2:34Biogen Idec Care Deeply Day 2014
Biogen Idec Care Deeply Day 2014Biogen Idec Care Deeply Day 2014
This September Biogen Idec held it's 4th Annual Care Deeply Day, where employees volunteer across the globe in their local communities. The Biogen Idec Care Deeply Volunteer Day is part of the company’s philanthropic focus on patients, science education and supporting local community needs. This was our largest Care Deeply Day ever with over 2900 employees participating in over 140 Projects, volunteering over 14,500 hours in 27 countries. #CareDeeplyDay
- Abbott Laboratories
- Acorda Therapeutics
- Activision Blizzard
- Adobe Systems
- Adolor Corporation
- Akamai Technologies
- Alan B. Glassberg
- Alcon
- Alefacept
- Alexander J. Denner
- Alkermes (company)
- Allergan
- Altera
- Alza
- Amazon.com
- Amevive
- Amgen
- Anne B. Young
- Apollo Group
- Apple Inc.
- Applied Materials
- ARYx Therapeutics
- Asset
- Astellas Pharma
- Australia
- Austria
- Autodesk
- Autoimmune disorders
- Avago Technologies
- Avax Technologies
- AVI BioPharma
- Avonex
- Baidu
- Barr Pharmaceuticals
- Baxter International
- Bed Bath & Beyond
- Benelux
- Biogen Idec
- Biolex
- Biotechnology
- Biovest
- Biovista
- BMC Software
- Bristol-Myers Squibb
- Broadcom
- Bruce R. Ross
- CA Technologies
- Canada
- Cancer
- CancerVax
- Carl Icahn
- Cecil Pickett
- Celgene
- Cell Therapeutics
- Cephalon
- Cerner
- Chairman
- Charles Weissmann
- Check Point
- China
- Cisco Systems
- Citrix Systems
- Combe Incorporated
- Comcast
- Costco
- CoTherix
- Covance
- Covidien
- Crohn's disease
- Crohns disease
- Ctrip
- Cutter Laboratories
- CytoSport
- CytRx
- Danco Laboratories
- Dell
- Denmark
- Dentsply
- Dimethyl fumarate
- DirecTV
- DNAPrint Genomics
- Dollar Tree
- EBay
- Electronic Arts
- Elorac
- Endo Pharmaceuticals
- Equity (finance)
- Ester
- Ethicon Endo-Surgery
- Ethicon Inc.
- Expedia, Inc.
- Express Scripts
- F5 Networks
- Fastenal
- Finland
- Fiserv
- Flextronics
- Forest Laboratories
- Fossil, Inc.
- France
- Fumaderm
- Fumaric acid
- Garmin
- Genentech
- Geneva
- Genta (company)
- GenVec
- George A. Scangos
- Germany
- Gilead Sciences
- Harvard
- Henry Schein
- Hillerød
- Hospira
- Howard Birndorf
- Ibritumomab tiuxetan
- ImClone Systems
- India
- Infosys
- Intel Corporation
- Interferon beta-1a
- Interferon-alpha
- Intuit
- Intuitive Surgical
- Ireland
- ISTA Pharmaceuticals
- Italy
- Ivax Corporation
- Ivor Royston
- Japan
- Johnson & Johnson
- Kendall Square
- Kinetic Concepts
- King Pharmaceuticals
- Kinray
- KLA Tencor
- KV Pharmaceutical
- Lam Research
- Lawrence C. Best
- Liberty Interactive
- Life Technologies
- Linear Technology
- Lynn Schenk
- Marijn E. Dekkers
- Massachusetts
- Mattel
- McKesson Corporation
- McNeil Laboratories
- Melior Discovery
- Mentholatum
- Merck & Co.
- Merger
- Microchip Technology
- Micron Technology
- Microsoft
- Miles Laboratories
- Monster Beverage
- Multiple sclerosis
- Mylan
- Myriad Genetics
- Nancy L. Leaming
- NASDAQ
- NASDAQ-100
- Natalizumab
- Net income
- NetApp
- Netflix
- Neurology
- News Corporation
- Norway
- Novartis
- Nuvelo
- Nvidia
- O'Reilly Auto Parts
- Oracle Corporation
- Ortho Pharmaceutical
- OSI Pharmaceuticals
- Paccar
- Par Pharmaceutical
- Parke-Davis
- Paychex
- Perrigo
- Pfizer
- Phillip A. Sharp
- Phillip Sharp
- Placebo
- Portal Companies
- Portugal
- Prasco Laboratories
- Priceline.com
- Procter & Gamble
- Proteon Therapeutics
- Proxy fight
- Psoriasis
- Public company
- PubMed Identifier
- Purdue Pharma
- Qualcomm
- Qualitest
- Randgold Resources
- Regeneron
- Repros Therapeutics
- Research In Motion
- Rheumatoid arthritis
- Richard C. Mulligan
- Rituxan
- Rituximab
- Robert W. Pangia
- Ross Stores
- S&P; 1500
- S&P; 500
- SanDisk
- Sanofi Aventis
- Savage Laboratories
- Schering-Plough
- Seagate Technology
- Serono
- Sigma-Aldrich
- Sirius XM Radio
- Spain
- Staples Inc.
- Starbucks
- Stericycle
- Sterling Drug
- Sweden
- Switzerland
- Symantec
- Tanox
- Tec Laboratories
- Template NASDAQ-100
- Texas Instruments
- Thomas F. Keller
- Ticker symbol
- Tiens Biotech Group
- Trevena Inc
- Trubion
- Tysabri
- United Kingdom
- United States
- United States dollar
- Upjohn
- Ventria Bioscience
- Verisign
- Virgin Media
- ViroPharma
- Vodafone
- Walter Gilbert
- Warner Chilcott
- Whole Foods Market
- Wikipedia Link rot
- Wyeth
- Wynn Resorts
- Xilinx
- Yahoo!
- Zevalin
- Zug
- Zurich University
- Élan
-
Biogen Idec is Biogen, Once Again
One of the original biotech companies, Biogen has been anchored in Cambridge, MA for nearly four decades. Today, we remain committed to our roots in science and innovation – and to bringing forward new medicines that will have a real impact on patients, caregivers and society. To us, that is science that truly matters. http://www.biogen.com -
Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US for Multiple Sclerosis
Dr. Barry Hendin, Chief of Neurology Service, Banner Good Samaritan Hospital and Clinical Professor of Neurology, University of Arizona comments on the U.S. FDA approval of Biogen Idec's TECFIDERA(TM) (dimethyl fumarate) for relapsing multiple sclerosis http://www.businesswire.com/news/home/20130327006385/en/Biogen-Idec%E2%80%99s-TECFIDERA%E2%84%A2-Dimethyl-Fumarate-Approved-First-Line -
Breaking Wave, kinetic sculpture located in the Biogen Idec lobby
Breaking Wave is an anamorphic kinetic sculpture created for our new headquarters in Cambridge, MA by Plebian Design and Hypersonic. If you’d like to visit in person, Breaking Wave runs Monday through Friday, 8am to 8pm at 255 Binney St. in Cambridge, MA. The sculpture is viewable from the street, or from inside the lobby. Feel free to ask the guards where the hidden images are, if you don’t find them. Breaking Wave tells the story of the search for patterns, and the surprising results that come by changing our point of view. 804 suspended spheres move in a wave-like formation. When the wave crests and breaks, the balls hover momentarily in a cloud. From almost anywhere in the room, this cloud is purely chaotic, but step into one of two hidden spots, and this apparent chaos shows a hidden... -
Manufacturing Drugs at Large Scale
Discover how Biogen Idec's industry-recognized expertise in manufacturing biologic therapies blends a combination of innovation and collaboration to ensure quality and reliable drugs. -
-
Sharp Says Biogen Idec Can Grow Alone or Be Acquired: Video
June 21 (Bloomberg) -- Phillip Sharp, co-founder of Biogen Idec Inc. and Alnylam Pharmaceuticals Inc., talks with Bloomberg's Mark Crumpton about the possibility that Biogen could be acquired and the outlook for the biotechnology industry and Alnylam. Sharp retired from the board of Biogen last year and remains a board member at Alnylam. He won the Nobel Prize in Medicine in 1993 and is a biology professor at Massachusetts Institute of Technology. (Source: Bloomberg) -
-
-
Biogen Idec Tapping into Denmark's Strong Biotech Cluster
Hear Ester Algeria from Biogen Idec explain why the pharmaceutical company has chosen to place a large production site in Denmark to benefit from the strong Danish biotech cluster and not least the large talent pool. Biogen Idec is a leading global biotechnological company with around 400 employees in Denmark working within fields like the production of pharmaceuticals for the treatment of multiple scleroses and biosimilars. Read more at www.investindk.com -
Biogen Idec Care Deeply Day 2014
This September Biogen Idec held it's 4th Annual Care Deeply Day, where employees volunteer across the globe in their local communities. The Biogen Idec Care Deeply Volunteer Day is part of the company’s philanthropic focus on patients, science education and supporting local community needs. This was our largest Care Deeply Day ever with over 2900 employees participating in over 140 Projects, volunteering over 14,500 hours in 27 countries. #CareDeeplyDay
Biogen Idec is Biogen, Once Again
- Order: Reorder
- Duration: 1:31
- Updated: 23 Mar 2015
- views: 3164
One of the original biotech companies, Biogen has been anchored in Cambridge, MA for nearly four decades. Today, we remain committed to our roots in science and...
One of the original biotech companies, Biogen has been anchored in Cambridge, MA for nearly four decades. Today, we remain committed to our roots in science and innovation – and to bringing forward new medicines that will have a real impact on patients, caregivers and society. To us, that is science that truly matters. http://www.biogen.com
wn.com/Biogen Idec Is Biogen, Once Again
One of the original biotech companies, Biogen has been anchored in Cambridge, MA for nearly four decades. Today, we remain committed to our roots in science and innovation – and to bringing forward new medicines that will have a real impact on patients, caregivers and society. To us, that is science that truly matters. http://www.biogen.com
- published: 23 Mar 2015
- views: 3164
Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US for Multiple Sclerosis
- Order: Reorder
- Duration: 3:21
- Updated: 28 Mar 2013
- views: 1814
Dr. Barry Hendin, Chief of Neurology Service, Banner Good Samaritan Hospital and Clinical Professor of Neurology, University of Arizona comments on the U.S. FDA...
Dr. Barry Hendin, Chief of Neurology Service, Banner Good Samaritan Hospital and Clinical Professor of Neurology, University of Arizona comments on the U.S. FDA approval of Biogen Idec's TECFIDERA(TM) (dimethyl fumarate) for relapsing multiple sclerosis
http://www.businesswire.com/news/home/20130327006385/en/Biogen-Idec%E2%80%99s-TECFIDERA%E2%84%A2-Dimethyl-Fumarate-Approved-First-Line
wn.com/Biogen Idec's Tecfidera™ (Dimethyl Fumarate) Approved In US For Multiple Sclerosis
Dr. Barry Hendin, Chief of Neurology Service, Banner Good Samaritan Hospital and Clinical Professor of Neurology, University of Arizona comments on the U.S. FDA approval of Biogen Idec's TECFIDERA(TM) (dimethyl fumarate) for relapsing multiple sclerosis
http://www.businesswire.com/news/home/20130327006385/en/Biogen-Idec%E2%80%99s-TECFIDERA%E2%84%A2-Dimethyl-Fumarate-Approved-First-Line
- published: 28 Mar 2013
- views: 1814
Breaking Wave, kinetic sculpture located in the Biogen Idec lobby
- Order: Reorder
- Duration: 3:29
- Updated: 04 Sep 2014
- views: 53801
Breaking Wave is an anamorphic kinetic sculpture created for our new headquarters in Cambridge, MA by Plebian Design and Hypersonic. If you’d like to visit in p...
Breaking Wave is an anamorphic kinetic sculpture created for our new headquarters in Cambridge, MA by Plebian Design and Hypersonic. If you’d like to visit in person, Breaking Wave runs Monday through Friday, 8am to 8pm at 255 Binney St. in Cambridge, MA. The sculpture is viewable from the street, or from inside the lobby. Feel free to ask the guards where the hidden images are, if you don’t find them.
Breaking Wave tells the story of the search for patterns, and the surprising results that come by changing our point of view. 804 suspended spheres move in a wave-like formation. When the wave crests and breaks, the balls hover momentarily in a cloud. From almost anywhere in the room, this cloud is purely chaotic, but step into one of two hidden spots, and this apparent chaos shows a hidden pattern. From the first, a labyrinth hints at the search for knowledge, and from the second, a Fibonacci spiral inspired flower reminds us of the natural order and patterns found in nature.
Scientists search through billions of experimental data points in order to find patterns to develop new drugs, to treat diseases. Without a particular framework or perspective, these are just 0’s and 1’s, with no form or information. But with the perspective of an understanding of molecular dynamics, these data points create a clear picture about the hidden dynamics within the body, and allow scientists to craft drugs to successfully treat these diseases.
This concept was designed with pencil, paper, and processing. The structure was designed in Solidworks. The piece was built with many hands, and several miles of wire rope.
Please check out "Order from Chaos" vimeo.com/102339558 for a making-of video by Alberta Chu's ASKlabs.
To learn more about the project a link to the project visit:
http://www.hypersonic.cc/projects/breakingwave
Credits:
Breaking Wave by Plebian Design and Hypersonic
Project Management Small Design Firm
Lighting Design David Weiner Design
Material Development Lightfast D B
Concept Rendering Carl Albrecht
The creators of the video send a special thanks to:
Ed Dondero, Melissa Kendis, and Dan McIntyre at Biogen-Idec, Jenna Fizel, Nathan Lachenmyer, David Small, Heather Blind, Alberta Chu, Kasumi Hinouchi, Neal Mayer, Lauren McCarthy, Kyle McDonald, JB Michel, Dan Paluska, Chris Parlato, Plus Fabrication, Scott Taylor, Sosolimited, Chris Danemayer.
Music by knolls
wn.com/Breaking Wave, Kinetic Sculpture Located In The Biogen Idec Lobby
Breaking Wave is an anamorphic kinetic sculpture created for our new headquarters in Cambridge, MA by Plebian Design and Hypersonic. If you’d like to visit in person, Breaking Wave runs Monday through Friday, 8am to 8pm at 255 Binney St. in Cambridge, MA. The sculpture is viewable from the street, or from inside the lobby. Feel free to ask the guards where the hidden images are, if you don’t find them.
Breaking Wave tells the story of the search for patterns, and the surprising results that come by changing our point of view. 804 suspended spheres move in a wave-like formation. When the wave crests and breaks, the balls hover momentarily in a cloud. From almost anywhere in the room, this cloud is purely chaotic, but step into one of two hidden spots, and this apparent chaos shows a hidden pattern. From the first, a labyrinth hints at the search for knowledge, and from the second, a Fibonacci spiral inspired flower reminds us of the natural order and patterns found in nature.
Scientists search through billions of experimental data points in order to find patterns to develop new drugs, to treat diseases. Without a particular framework or perspective, these are just 0’s and 1’s, with no form or information. But with the perspective of an understanding of molecular dynamics, these data points create a clear picture about the hidden dynamics within the body, and allow scientists to craft drugs to successfully treat these diseases.
This concept was designed with pencil, paper, and processing. The structure was designed in Solidworks. The piece was built with many hands, and several miles of wire rope.
Please check out "Order from Chaos" vimeo.com/102339558 for a making-of video by Alberta Chu's ASKlabs.
To learn more about the project a link to the project visit:
http://www.hypersonic.cc/projects/breakingwave
Credits:
Breaking Wave by Plebian Design and Hypersonic
Project Management Small Design Firm
Lighting Design David Weiner Design
Material Development Lightfast D B
Concept Rendering Carl Albrecht
The creators of the video send a special thanks to:
Ed Dondero, Melissa Kendis, and Dan McIntyre at Biogen-Idec, Jenna Fizel, Nathan Lachenmyer, David Small, Heather Blind, Alberta Chu, Kasumi Hinouchi, Neal Mayer, Lauren McCarthy, Kyle McDonald, JB Michel, Dan Paluska, Chris Parlato, Plus Fabrication, Scott Taylor, Sosolimited, Chris Danemayer.
Music by knolls
- published: 04 Sep 2014
- views: 53801
Manufacturing Drugs at Large Scale
- Order: Reorder
- Duration: 3:15
- Updated: 02 Feb 2012
- views: 17187
Discover how Biogen Idec's industry-recognized expertise in manufacturing biologic therapies blends a combination of innovation and collaboration to ensure qual...
Discover how Biogen Idec's industry-recognized expertise in manufacturing biologic therapies blends a combination of innovation and collaboration to ensure quality and reliable drugs.
wn.com/Manufacturing Drugs At Large Scale
Discover how Biogen Idec's industry-recognized expertise in manufacturing biologic therapies blends a combination of innovation and collaboration to ensure quality and reliable drugs.
- published: 02 Feb 2012
- views: 17187
The Next Big Thing In Biotech: Biogen Idec
- Order: Reorder
- Duration: 2:28
- Updated: 22 Oct 2011
- views: 2261
The Next Big Thing In Biotech: Biogen Idec
The Next Big Thing In Biotech: Biogen Idec
wn.com/The Next Big Thing In Biotech Biogen Idec
Sharp Says Biogen Idec Can Grow Alone or Be Acquired: Video
- Order: Reorder
- Duration: 5:05
- Updated: 23 Mar 2012
- views: 429
June 21 (Bloomberg) -- Phillip Sharp, co-founder of Biogen Idec Inc. and Alnylam Pharmaceuticals Inc., talks with Bloomberg's Mark Crumpton about the possibilit...
June 21 (Bloomberg) -- Phillip Sharp, co-founder of Biogen Idec Inc. and Alnylam Pharmaceuticals Inc., talks with Bloomberg's Mark Crumpton about the possibility that Biogen could be acquired and the outlook for the biotechnology industry and Alnylam.
Sharp retired from the board of Biogen last year and remains a board member at Alnylam. He won the Nobel Prize in Medicine in 1993 and is a biology professor at Massachusetts Institute of Technology. (Source: Bloomberg)
wn.com/Sharp Says Biogen Idec Can Grow Alone Or Be Acquired Video
June 21 (Bloomberg) -- Phillip Sharp, co-founder of Biogen Idec Inc. and Alnylam Pharmaceuticals Inc., talks with Bloomberg's Mark Crumpton about the possibility that Biogen could be acquired and the outlook for the biotechnology industry and Alnylam.
Sharp retired from the board of Biogen last year and remains a board member at Alnylam. He won the Nobel Prize in Medicine in 1993 and is a biology professor at Massachusetts Institute of Technology. (Source: Bloomberg)
- published: 23 Mar 2012
- views: 429
(BIIB) Biogen Idec, Inc.
- Order: Reorder
- Duration: 4:37
- Updated: 07 Jan 2015
- views: 91
(BIIB) Biogen Idec, Inc.
- Order: Reorder
- Duration: 6:27
- Updated: 23 Jul 2014
- views: 82
Biogen Idec Tapping into Denmark's Strong Biotech Cluster
- Order: Reorder
- Duration: 2:26
- Updated: 25 Apr 2013
- views: 688
Hear Ester Algeria from Biogen Idec explain why the pharmaceutical company has chosen to place a large production site in Denmark to benefit from the strong Dan...
Hear Ester Algeria from Biogen Idec explain why the pharmaceutical company has chosen to place a large production site in Denmark to benefit from the strong Danish biotech cluster and not least the large talent pool.
Biogen Idec is a leading global biotechnological company with around 400 employees in Denmark working within fields like the production of pharmaceuticals for the treatment of multiple scleroses and biosimilars.
Read more at www.investindk.com
wn.com/Biogen Idec Tapping Into Denmark's Strong Biotech Cluster
Hear Ester Algeria from Biogen Idec explain why the pharmaceutical company has chosen to place a large production site in Denmark to benefit from the strong Danish biotech cluster and not least the large talent pool.
Biogen Idec is a leading global biotechnological company with around 400 employees in Denmark working within fields like the production of pharmaceuticals for the treatment of multiple scleroses and biosimilars.
Read more at www.investindk.com
- published: 25 Apr 2013
- views: 688
Biogen Idec Care Deeply Day 2014
- Order: Reorder
- Duration: 2:34
- Updated: 03 Oct 2014
- views: 1665
This September Biogen Idec held it's 4th Annual Care Deeply Day, where employees volunteer across the globe in their local communities.
The Biogen Idec Care ...
This September Biogen Idec held it's 4th Annual Care Deeply Day, where employees volunteer across the globe in their local communities.
The Biogen Idec Care Deeply Volunteer Day is part of the company’s philanthropic focus on patients, science education and supporting local community needs.
This was our largest Care Deeply Day ever with over 2900 employees participating in over 140 Projects, volunteering over 14,500 hours in 27 countries. #CareDeeplyDay
wn.com/Biogen Idec Care Deeply Day 2014
This September Biogen Idec held it's 4th Annual Care Deeply Day, where employees volunteer across the globe in their local communities.
The Biogen Idec Care Deeply Volunteer Day is part of the company’s philanthropic focus on patients, science education and supporting local community needs.
This was our largest Care Deeply Day ever with over 2900 employees participating in over 140 Projects, volunteering over 14,500 hours in 27 countries. #CareDeeplyDay
- published: 03 Oct 2014
- views: 1665
close fullscreen
- Playlist
- Chat
close fullscreen
- Playlist
- Chat
1:31
Biogen Idec is Biogen, Once Again
One of the original biotech companies, Biogen has been anchored in Cambridge, MA for nearl...
published: 23 Mar 2015
Biogen Idec is Biogen, Once Again
Biogen Idec is Biogen, Once Again
- Report rights infringement
- published: 23 Mar 2015
- views: 3164
3:21
Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US for Multiple Sclerosis
Dr. Barry Hendin, Chief of Neurology Service, Banner Good Samaritan Hospital and Clinical ...
published: 28 Mar 2013
Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US for Multiple Sclerosis
Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Approved in US for Multiple Sclerosis
- Report rights infringement
- published: 28 Mar 2013
- views: 1814
3:29
Breaking Wave, kinetic sculpture located in the Biogen Idec lobby
Breaking Wave is an anamorphic kinetic sculpture created for our new headquarters in Cambr...
published: 04 Sep 2014
Breaking Wave, kinetic sculpture located in the Biogen Idec lobby
Breaking Wave, kinetic sculpture located in the Biogen Idec lobby
- Report rights infringement
- published: 04 Sep 2014
- views: 53801
3:15
Manufacturing Drugs at Large Scale
Discover how Biogen Idec's industry-recognized expertise in manufacturing biologic therapi...
published: 02 Feb 2012
Manufacturing Drugs at Large Scale
Manufacturing Drugs at Large Scale
- Report rights infringement
- published: 02 Feb 2012
- views: 17187
2:28
The Next Big Thing In Biotech: Biogen Idec
The Next Big Thing In Biotech: Biogen Idec
published: 22 Oct 2011
The Next Big Thing In Biotech: Biogen Idec
The Next Big Thing In Biotech: Biogen Idec
- Report rights infringement
- published: 22 Oct 2011
- views: 2261
5:05
Sharp Says Biogen Idec Can Grow Alone or Be Acquired: Video
June 21 (Bloomberg) -- Phillip Sharp, co-founder of Biogen Idec Inc. and Alnylam Pharmaceu...
published: 23 Mar 2012
Sharp Says Biogen Idec Can Grow Alone or Be Acquired: Video
Sharp Says Biogen Idec Can Grow Alone or Be Acquired: Video
- Report rights infringement
- published: 23 Mar 2012
- views: 429
4:37
(BIIB) Biogen Idec, Inc.
(BIIB) Biogen Idec, Inc.
published: 07 Jan 2015
(BIIB) Biogen Idec, Inc.
(BIIB) Biogen Idec, Inc.
- Report rights infringement
- published: 07 Jan 2015
- views: 91
6:27
(BIIB) Biogen Idec, Inc.
(BIIB) Biogen Idec, Inc.
published: 23 Jul 2014
(BIIB) Biogen Idec, Inc.
(BIIB) Biogen Idec, Inc.
- Report rights infringement
- published: 23 Jul 2014
- views: 82
2:26
Biogen Idec Tapping into Denmark's Strong Biotech Cluster
Hear Ester Algeria from Biogen Idec explain why the pharmaceutical company has chosen to p...
published: 25 Apr 2013
Biogen Idec Tapping into Denmark's Strong Biotech Cluster
Biogen Idec Tapping into Denmark's Strong Biotech Cluster
- Report rights infringement
- published: 25 Apr 2013
- views: 688
2:34
Biogen Idec Care Deeply Day 2014
This September Biogen Idec held it's 4th Annual Care Deeply Day, where employees volunteer...
published: 03 Oct 2014
Biogen Idec Care Deeply Day 2014
Biogen Idec Care Deeply Day 2014
- Report rights infringement
- published: 03 Oct 2014
- views: 1665
Biogen Idec is Biogen, Once Again...
Biogen Idec's TECFIDERA™ (Dimethyl Fumarate) Appro...
Breaking Wave, kinetic sculpture located in the Bi...
Manufacturing Drugs at Large Scale...
The Next Big Thing In Biotech: Biogen Idec...
Sharp Says Biogen Idec Can Grow Alone or Be Acquir...
(BIIB) Biogen Idec, Inc....
(BIIB) Biogen Idec, Inc....
Biogen Idec Tapping into Denmark's Strong Biotech ...
